RxDoctor Payments Data

Giuseppe Limandri, MD

Cardiovascular Disease · Morristown, NJNPI 1548234628

Payments from drug & device makers

$1,716in general payments, 2019–2025

Across 132 payments — averaging $13.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$370
  • Amgen$206
  • Merck$179
  • Sanofi-aventis U.S. LLC$175
  • Pfizer$152
  • Johnson & Johnson$97
  • plus $538 from 13 others

What the payments were for

  • Food & beverage$1,70399%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,716 in reported general payments places this provider in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$215,245
Medicare patients
1,331
Services billed
3,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban322$430,626
VyndamaxTafamidis13$290,097
XareltoRivaroxaban62$84,693
MultaqDronedarone Hcl55$79,160
EntrestoSacubitril/Valsartan53$78,168
Repatha SureclickEvolocumab46$41,845
JardianceEmpagliflozin36$38,614
FarxigaDapagliflozin Propanediol26$34,261
BrilintaTicagrelor18$16,787
VascepaIcosapent Ethyl19$12,640
Metoprolol Succinate629$10,409
Nebivolol Hcl77$5,003
Atorvastatin Calcium460$4,079
Rosuvastatin Calcium303$3,655
Ranolazine ErRanolazine22$3,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$152$720,722335 claims
Johnson & JohnsonXarelto$97$84,69362 claims
Sanofi-aventis U.S. LLCMultaq$175$79,16055 claims
NovartisEntresto$370$78,16853 claims
AstraZenecaFarxiga, Brilinta$30$51,04944 claims
Boehringer IngelheimJardiance$67$38,61436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →